Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Cardio-Kidney Trials Present Obstacles
Disease Discoveries

Cardio-Kidney Trials Present Obstacles

By Will DossFeb 5, 2021
Share
Facebook Twitter Email
Ravi Patel, ’12 MD, MSc ’19 GME, instructor of Medicine in the Division of Cardiology, was first author of the review article published in Circulation.

A new class of drugs shows benefit for both cardiovascular and kidney conditions, but scientists should be cautious in designing trials that include both cardiovascular and kidney outcomes in the same analysis, according to a recent review published in Circulation.

“It’s an exciting time, but in order to really understand the benefits of new drugs, careful thought is required with regard to combining endpoints in future trials,” said Ravi Patel, ’12 MD, MSc ’19 GME, instructor of Medicine in the Division of Cardiology and first author of the review.

Kidney disease and cardiovascular disease have a high degree of overlap. People with hypertension, heart failure or diabetes often tend to have kidney disease as well, according to Patel.

A new class of drugs, sodium-glucose cotransporter-2 inhibitors, have shown clinically significant benefits in both cardiovascular disease and kidney disease. These drugs, along with the joint nature of cardiovascular and kidney conditions, have increased interest in establishing standards for measuring concordant cardio-kidney benefits in future clinical trials.

“There’s an idea that we might be able to evaluate the effectiveness on both outcomes rather than in two separate trials, with a time and cost savings,” Patel said.

However, this approach could present several problems. While cardiovascular outcomes such as heart failure occur relatively frequently, serious kidney outcomes such as damage requiring dialysis are much rarer. Using both heart failure and dialysis as end points in a trial is a mismatch, as the heart outcomes could overwhelm and mask the kidney outcomes in analysis, Patel said.

One possible solution is to measure kidney biomarkers in blood, rather than use a clinical endpoint like dialysis, but that too comes with issues, according to Patel.

“These changes can occur transiently, and they don’t necessarily mean that one’s kidney function will decline over the long-term,” Patel said. “It may not be an accurate predictor of requiring dialysis, so it can complicate things.”

However, these obstacles are not insurmountable. These issues must be considered and dealt with, but innovation in clinical trials is never impossible, according to Patel.

“In order to really understand the cardiac and kidney benefits of therapies for our patients, it requires a lot of thought from clinical trialists,” Patel said. “Then, I think we’ll have the best shot at identifying therapies for our patients to improve both aspects of their health and ultimately, help them live longer.”

This study was supported by the National Institutes of Health National Center for Advancing Translational Sciences grant KL2TR001424.

Cardiology Medicine Research
Share. Facebook Twitter Email

Related Posts

Longtime Alcohol Consumption Speeds Up Biological Aging 

Feb 3, 2023

Grant Provides Imaging Technology to Department of Ophthalmology

Feb 2, 2023

Gender-Affirming Hormones Improve Mental Health in Transgender and Nonbinary Youth

Feb 2, 2023

Comments are closed.

Latest News

Longtime Alcohol Consumption Speeds Up Biological Aging 

Feb 3, 2023

Grant Provides Imaging Technology to Department of Ophthalmology

Feb 2, 2023

Gender-Affirming Hormones Improve Mental Health in Transgender and Nonbinary Youth

Feb 2, 2023

Investigating the Connection Between Steps and Heart Disease Risk

Feb 1, 2023

Medical School Faculty Named AAAS Fellows

Jan 31, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
Feinberg_In_Vivo_20221209_tcrawford-24
Feinberg_In_Vivo_20221209_tcrawford-16
Feinberg_In_Vivo_20221209_tcrawford-14
Feinberg_In_Vivo_20221209_tcrawford-5
Feinberg_In_Vivo_20221209_tcrawford-6
Feinberg_In_Vivo_20221209_tcrawford-10
Feinberg_In_Vivo_20221209_tcrawford-8
Feinberg_In_Vivo_20221209_tcrawford-18
Feinberg_In_Vivo_20221209_tcrawford
Feinberg_In_Vivo_20221209_tcrawford-23
Feinberg_In_Vivo_20221209_tcrawford-25
Feinberg_In_Vivo_20221209_tcrawford-26

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.